Compare Davita Inc (DVA) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares Core High Dividend ETF — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while iShares Core High Dividend ETF trades at $27.6. Which is the better fit depends on your goals.
| DVA | HDV | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | — |
52-Week High | $235.71 | $28.09 |
52-Week Low | $103.87 | $23.63 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
HDV (iShares Core High Dividend ETF) trades at $27.93, up 0.83% with a bullish technical signal from moving averages. The ETF focuses on high-quality U.S. dividend stocks with a 3.0% yield, emphasizing defensive sectors like healthcare and energy. Recent performance shows strong total returns with lower volatility than the S&P 500, supported by a 1:5 stock split executed in April 2026.
HDV offers attractive income generation with quality screening, though its concentrated energy exposure (21.56%) introduces sector-specific volatility. The ETF's low expense ratio and defensive positioning provide stability, but investors should monitor oil price sensitivity. Long-term dividend growth potential remains favorable amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
